Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03253094 · ClinicalTrials.gov registry record · Phase 2
Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis
A Phase 2 study, sponsored by Scynexis.
- Completed
- Registry status
- Phase 2
- Development phase
- 186
- Enrollment target
NCT03253094 is a Phase 2 study that has completed, run by Scynexis. The registered enrollment target is 186 participants.
The verdict
NCT03253094, a Phase 2 study, has completed, sponsored by Scynexis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 186 participants
- Enrollment target
Study Summary
This is a multicenter, randomized, double-blind, double-dummy, active-controlled, dose-finding study to compare the efficacy, safety and tolerability of oral SCY-078 versus oral fluconazole in adult female subjects 18 years and older with moderate to severe Acute Vulvovaginal Candidiasis (AVVC). Approximately 180 eligible subjects (30 subjects per treatment group) will be enrolled and randomized into the study.
Interventions
- DRUG Fluconazole
- DRUG SCY-078
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 186 participants |
| Start Date | 2017-08-01 |
| Est. Completion | 2018-05-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03253094
The ClinicalTrials.gov registry entry for NCT03253094 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 186 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Scynexis, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fluconazole is the first listed.
NCT03253094 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03253094 about?
NCT03253094 is a clinical study titled "Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis". This is a multicenter, randomized, double-blind, double-dummy, active-controlled, dose-finding study to compare the efficacy, safety and tolerability of oral SCY-078 versus oral fluconazole in adult female subjects 18 years and older with moderate to severe Acute Vulvovaginal Candidiasis (AVVC). App...
What is the current status of trial NCT03253094?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 186 participants. The study started on 2017-08-01. Estimated completion is 2018-05-04.
What interventions are being tested in trial NCT03253094?
The interventions under investigation include: Fluconazole (DRUG), SCY-078 (DRUG).
Who is sponsoring clinical trial NCT03253094?
This trial is sponsored by Scynexis, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.